Table 2 Characteristics associated with anticoagulant treatment
Characteristic | Rivaroxaban (n=220) | Standard therapy (n=219) |
|---|---|---|
At least one dose of a study drug received, n (%) | 219 (99.5) | 218 (99.5) |
Intended duration of treatment, n (%) | ||
3 months | 56 (25.5) | 55 (25.1) |
6 months | 131 (59.5) | 131 (59.8) |
12 months | 33 (15.0) | 33 (15.1) |
Mean study duration, days | 198.5 | 191.3 |
Mean study treatment duration, days | 162.2 | 155.2 |
Reasons for premature discontinuation of treatment, n (%) | ||
Any reason | 27 (12.3) | 37 (16.9) |
Adverse event | 14 (6.4) | 15 (6.8) |
Consent withdrawn | 5 (2.3) | 14 (6.4) |
Loss to follow-up | 4 (1.8) | 3 (1.4) |